Alzheimer Disease

Biotech company announces results of Alzheimer study

Published in Gene Therapy Weekly, November 11th, 2004

Prana Biotechnology Limited (NASDAQ:PRAN)(NASDAQ:ASX:)(NASDAQ:PBT) announced the results of the open label 84-week "extension study" of its phase II clinical trial of PBT-1 (clioquinol) study, also known as the CQAD study.

The data from the formal treatment phase of the study was published in the December 2003 issue of Archives of Neurology.

All participants from the original 36-week blinded and placebo-controlled portion of the phase II trial were offered the opportunity to continue the PBT-1 treatment on an open label basis for an additional 48 weeks. 18 (66.7%) out of 27 patients elected to start the CQADEX extension study. Nine patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry